Phase I/II Study of the Combination of Bendamustine, Rituximab and MK-2206 in the Treatment of Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Next Previous
Trial Profile

Phase I/II Study of the Combination of Bendamustine, Rituximab and MK-2206 in the Treatment of Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2017

At a glance

  • Drugs MK 2206 (Primary) ; Bendamustine; Rituximab
  • Indications Chronic lymphocytic leukaemia; Lymphoid leukaemia
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 01 Aug 2017 Results published in the American Journal of Hematology
    • 10 Jun 2017 Biomarkers information updated
    • 20 May 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top